登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Bevacizumab >BEB-BY13

Biotinylated Anti-Bevacizumab Antibody (AY13) (recommended for PK/PD)

抗体来源(Source)

Biotinylated Anti-Bevacizumab Antibody (AY13) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

克隆号(Clone)

AY13

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1 | kappa

抗体类型(Antibody Type)

Hybridoma Monoclonal

种属反应性(Reactivity)

Human

免疫原(Immunogen)

Bevacizumab.

特异性(Specificity)

Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

纯化(Purification)

Protein A purified/ Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Bevacizumab SDS-PAGE

Biotinylated Anti-Bevacizumab Antibody (AY13) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Bevacizumab ELISA

Detection of bevacizumab by bridging ELISA in serum. Immobilized Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) at 2 μg/mL, add increasing concentrations of bevacizumab (10% human serum) and then add Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.4 μg/mL (QC tested).

Protocol

Bevacizumab ELISA

Immobilized bevacizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) with a linear range of 0.78-25.5 ng/mL.

Protocol

Bevacizumab ELISA

ELISA analysis shows that the binding of bevacizumab to Human VEGF165, premium grade (Cat. No. VE5-H4210) was inhibited by increasing concentration of Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13). The concentration of bevacizumab used is 4 ng/mL.

Protocol

 

背景(Background)

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定